BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26979038)

  • 1. [NEW ANTIFUNGAL DRUGS FOR PREVENTION AND TREATMENT OF VISCERAL MYCOSES].
    Pilmis B; Lortholary O; Lanternier FL
    Rev Prat; 2015 Dec; 65(10):1334-9. PubMed ID: 26979038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isavuconazole: a role for the newest broad-spectrum triazole.
    Slavin MA; Thursky KA
    Lancet; 2016 Feb; 387(10020):726-8. PubMed ID: 26684608
    [No Abstract]   [Full Text] [Related]  

  • 3. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazonium sulfate for the treatment of fungal infection.
    Walker RC; Zeuli JD; Temesgen Z
    Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
    Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
    Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
    J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The future of antifungal agents].
    Maesaki S
    Rinsho Ketsueki; 2007 Jan; 48(1):26-35. PubMed ID: 17313074
    [No Abstract]   [Full Text] [Related]  

  • 9. [Outcome analysis of caspofungin in combination with voriconazole for treatment of 12 hematologic malignancies cases with invasive fungal infection].
    Sun HL; Zhou X; Shen YF
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):558-9. PubMed ID: 22338183
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical indications for newer antifungal agents.
    Naeger-Murphy N; Pile JC
    J Hosp Med; 2009 Feb; 4(2):102-11. PubMed ID: 19219926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Infectious diseases: progress in diagnosis and treatment. Topics: IV. Towards containing infectious diseases: 3. Development of new antifungal drugs].
    Yoshida M
    Nihon Naika Gakkai Zasshi; 2012 Nov; 101(11):3185-91. PubMed ID: 23342592
    [No Abstract]   [Full Text] [Related]  

  • 12. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pharmacological opportunities for the treatment of invasive mould diseases.
    Ledoux MP; Toussaint E; Denis J; Herbrecht R
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
    Guinea J; Bouza E
    Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antifungal therapy update: new drugs and medical uses].
    FortĂșn J
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():38-44. PubMed ID: 22305668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
    Wang JF; Xue Y; Zhu XB; Fan H
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New development in the treatment of deep-seated mycoses].
    Maesaki S
    Nihon Naika Gakkai Zasshi; 2007 Sep; 96(9):1993-8. PubMed ID: 17929445
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
    Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
    Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
    Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
    J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.